<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Lipoid proteinosis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Lipoid proteinosis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Lipoid proteinosis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Mazen Kurban, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jinane El Khoury, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jennifer L Hand, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Rosamaria Corona, MD, DSc
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Aug 10, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H2268572202">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Lipoid proteinosis (LP; MIM #247100), also known as Urbach-Wiethe disease or hyalinosis cutis et mucosae, is a rare autosomal recessive genodermatosis characterized by persistent voice hoarseness in infancy and accompanied by skin changes, such as fragility, discomfort, infiltrated papules and/or nodules over the skin, and mucosae [
         <a href="#rid1">
          1
         </a>
         ]. Affected individuals may also present with neurologic and psychiatric symptoms [
         <a href="#rid2">
          2
         </a>
         ]. The clinical manifestations result from the deposition of a hyaline material in the mucosae, skin, and brain tissue. LP is caused by variants in the extracellular matrix protein gene (
         <em>
          ECM1
         </em>
         ), located on chromosome 1q21.2 [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         This topic will review the genetics, pathogenesis, clinical features, and management of LP. Other causes of hoarseness in children are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/6304.html" rel="external">
          "Hoarseness in children: Evaluation"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1948424684">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Lipoid proteinosis (LP) is an exceedingly rare disease, with less than 500 cases reported in the literature [
         <a href="#rid2">
          2
         </a>
         ]. LP affects males and females equally [
         <a href="#rid3">
          3
         </a>
         ]. LP is present worldwide, although it has been reported with a higher frequency in the Northern Cape province of South Africa, including Namaqualand, owing to a common founder effect. The disease has been traced to a common German ancestor who settled in South Africa in the mid-17
         <sup>
          th
         </sup>
         century [
         <a href="#rid4">
          4
         </a>
         ]. Fifty-one cases of LP were reported from India [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1278759019">
         <span class="h1">
          GENETICS AND PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Lipoid proteinosis (LP) is an autosomal recessive genodermatosis caused by variants in the extracellular matrix protein gene (
         <em>
          ECM1)
         </em>
         , located on chromosome 1q21.2 [
         <a href="#rid3">
          3
         </a>
         ]. Heterozygous carriers, estimated to be 1 in 400 of the general population, are asymptomatic [
         <a href="#rid2">
          2
         </a>
         ]. Over 50 loss-of-function variants, predominantly missense and nonsense variants, have been reported [
         <a href="#rid6">
          6-8
         </a>
         ]. Variants in all 10 exons of the
         <em>
          ECM1
         </em>
         gene have been reported, with the majority occurring in exons 6 and 7 [
         <a href="#rid9">
          9
         </a>
         ]. Interestingly, in the largest group of patients with LP from the Namaqualand region of the Northern Cape of South Africa, a single nonsense variant in exon 7 (pQ276X) was found to be common to all the subjects studied [
         <a href="#rid4">
          4
         </a>
         ] due to a founder effect.
        </p>
        <p>
         The normally functioning
         <em>
          ECM1
         </em>
         gene has four splice variants:
         <em>
          ECM1a
         </em>
         , which contains 10 exons;
         <em>
          ECM1b
         </em>
         , which lacks exon 7; and
         <em>
          ECM1c
         </em>
         and
         <em>
          ECM1d
         </em>
         , which give rise to a truncated 57 amino acid protein [
         <a href="#rid10">
          10,11
         </a>
         ]. Exon 7 is not found in the
         <em>
          ECM1b
         </em>
         variant, and thus, variants in exon 7 will still yield a normal ECM1b protein. Therefore, it was thought that variants in exon 7 would carry a better prognosis compared with variants in other exons [
         <a href="#rid7">
          7,8
         </a>
         ]. However, it has been shown that there are no significant differences in the severity of the mucosal, cutaneous, neurologic, and neuropsychologic features that correlate with any particular variant [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
         ECM1 is an extracellular protein that has been implicated in endochondral bone formation, angiogenesis, and tumor biology [
         <a href="#rid12">
          12
         </a>
         ]. ECM1 seems to have an essential structural role in the skin and acts by interacting with a number of scaffolding proteins, such as the laminin 332 beta 3 chain and fibulin-3 [
         <a href="#rid12">
          12
         </a>
         ]. Moreover, ECM1 inhibits the activity of matrix metalloproteinase-9 (MMP-9) through the interaction with the C-terminal second tandem repeat (exon 7) of
         <em>
          ECM1
         </em>
         [
         <a href="#rid13">
          13
         </a>
         ]. Thus, a decrease in ECM1 causes an increase in MMP-9 activity, which contributes to the hyaline changes seen in LP [
         <a href="#rid13">
          13
         </a>
         ]. This may be of particular importance in the pathogenesis of the neurologic changes seen in LP [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
         A number of alterations pertaining to the architecture of the skin microvasculature, such as increased thickness of the basement membrane surrounding dermal blood vessels, have been described in LP [
         <a href="#rid14">
          14,15
         </a>
         ]. Additional gross anomalies of the normal dermal vascular architecture include the presence of enlarged vessels that are orientated parallel to the dermal-epidermal junction as well as a loss of the normal papillary capillary loops [
         <a href="#rid14">
          14
         </a>
         ]. In one study, lesional skin of a patient with LP was found to be lacking lymphatic tissue as compared with nonlesional skin in the same individual, leading to the hypothesis that a failure of lymphangiogenesis may contribute to the pathogenesis of the mucocutaneous findings in LP [
         <a href="#rid15">
          15
         </a>
         ]. Moreover, a study showed that oxidative stress could play a role in the pathogenesis of LP [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1802190023">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H3945091072">
         <span class="h2">
          Mucocutaneous manifestations
         </span>
         <span class="headingEndMark">
          —
         </span>
         The classic presenting symptom of lipoid proteinosis (LP) is a weak cry and a persistent hoarse voice during the first year of life that is caused by the deposition of hyaline material within the laryngeal mucosa. Infiltration of the oral mucosa during childhood results in stiffening of the frenulum and tongue, restricted protrusion of the tongue, and, possibly, discomfort  (
         <a class="graphic graphic_picture graphicRef120701" href="/z/d/graphic/120701.html" rel="external">
          picture 1A
         </a>
         ) [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         Other oral manifestations include thickened lips with fissuring at the commissures, as well as cobblestoning of the mucosa  (
         <a class="graphic graphic_picture graphicRef120725" href="/z/d/graphic/120725.html" rel="external">
          picture 2
         </a>
         ) and gingival hypertrophy [
         <a href="#rid17">
          17
         </a>
         ]. The finding of macroglossia with lateral crenation has been reported in LP  (
         <a class="graphic graphic_picture graphicRef120731" href="/z/d/graphic/120731.html" rel="external">
          picture 1B
         </a>
         ) [
         <a href="#rid18">
          18,19
         </a>
         ]. A review of the literature including 137 patients with oral manifestations showed that the most common site of oral involvement in patients with LP is the tongue (68 percent), followed by the floor of the mouth (55.8 percent), the lips (43 percent), and buccal mucosa (40 percent) [
         <a href="#rid19">
          19
         </a>
         ]. The palate and the gingivae were rarely involved. Dental anomalies have been reported, albeit rarely [
         <a href="#rid7">
          7,17
         </a>
         ].
        </p>
        <p>
         The oropharynx may present infiltrated, waxy, yellowish papulonodules on examination [
         <a href="#rid20">
          20
         </a>
         ]. Laryngeal involvement may very rarely cause stridor and breathing difficulties that can warrant treatment with a tracheostomy [
         <a href="#rid21">
          21
         </a>
         ]. Recurrent obstruction of the parotid duct may cause parotitis [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p>
         Skin fragility may manifest in early childhood, resulting in spontaneous or trauma-induced development of vesicles and blisters over the face and extremities. These lesions heal with pox-like or acne-like scarring  (
         <a class="graphic graphic_picture graphicRef120726" href="/z/d/graphic/120726.html" rel="external">
          picture 3
         </a>
         ) [
         <a href="#rid4">
          4,22
         </a>
         ]. Typically, patients with LP develop beaded papules ("string of pearls") along the eyelid margins, known as moniliform blepharosis  (
         <a class="graphic graphic_picture graphicRef120730 graphicRef120728" href="/z/d/graphic/120730.html" rel="external">
          picture 4A-B
         </a>
         ). Infiltration of the skin worsens with trauma and leads to verrucous, hyperkeratotic plaques over frictional areas, particularly over the knuckles, elbows, knees, buttocks, and axillae  (
         <a class="graphic graphic_picture graphicRef120733" href="/z/d/graphic/120733.html" rel="external">
          picture 5
         </a>
         ) [
         <a href="#rid4">
          4
         </a>
         ]. Other cutaneous manifestations include alopecia and palmoplantar hyperkeratosis [
         <a href="#rid19">
          19,23
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4132878642">
         <span class="h3">
          Dermoscopic findings
         </span>
         <span class="headingEndMark">
          —
         </span>
         Dermoscopic findings of cutaneous lesions seen in LP include sulci and gyri with pale white, structureless areas, as well as lesions with a "pulpy" or "pulp-like" appearance  (
         <a class="graphic graphic_picture graphicRef130649" href="/z/d/graphic/130649.html" rel="external">
          picture 6
         </a>
         ) [
         <a href="#rid24">
          24
         </a>
         ]. These features may be variably seen in LP lesions, depending on the lesions, but vary depending on the type and location of lesions.
        </p>
        <p class="headingAnchor" id="H41259807">
         <span class="h2">
          Neurologic manifestations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Central nervous system involvement may be the predominant feature in LP, although the correct diagnosis may be elusive due to the lack of awareness of this rare condition [
         <a href="#rid2">
          2,25
         </a>
         ]. Neuropsychiatric findings are highly variable and include seizures, migraine, schizophrenia, anxiety, panic attacks, impaired memory, and abnormal emotional responses to perceived danger and fear [
         <a href="#rid2">
          2
         </a>
         ]. Symptoms may start during childhood or appear later in life. Early involvement of the face and buttocks in infancy has been suggested to be a predictor of neurologic manifestations later in life [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
         Dysfunction of the amygdala due to the presence of calcifications is thought to underlie most of the neuropsychiatric manifestations of LP (see
         <a class="local">
          'Neuroimaging findings'
         </a>
         below). The human amygdala comprises several distinct nuclei that differ in structure and function; the central-medial amygdala is instrumental in the execution of fear responses, whereas the basal, basolateral, and basomedial nuclei are involved in processing sensory information, including fear stimuli [
         <a href="#rid26">
          26-28
         </a>
         ].
        </p>
        <p>
         Manifestations due to dysfunction of the amygdala depend on the localization and extent of damage [
         <a href="#rid29">
          29
         </a>
         ]. As an example, an extensively studied patient with complete bilateral amygdala calcification exhibited a loss of fear response to stimuli, such as snakes and spiders, and lack of emotional face recognition [
         <a href="#rid27">
          27
         </a>
         ]. In contrast, patients with focal amygdala damage restricted to the basolateral nuclei exhibit a more hypervigilant response to fearful stimuli as well as a superior recognition of facial fear expression compared with control subjects [
         <a href="#rid30">
          30,31
         </a>
         ].
        </p>
        <p>
         Epilepsy is estimated to occur in approximately 30 percent of patients with LP [
         <a href="#rid32">
          32,33
         </a>
         ]. In one of the largest case series from the Northern Cape province of South Africa, 5 out of 24 subjects reported seizures, among which 2 had classic temporal lobe epilepsy with an aura characterized by a sensation of déjà vu [
         <a href="#rid4">
          4
         </a>
         ]. In a review of 41 cases of LP and epilepsy, 21 patients had bilateral amygdala calcification and an ictal semiology that was consistent with temporal lobe involvement; none of the 41 cases was reported to have ictal fear [
         <a href="#rid32">
          32
         </a>
         ]. In a retrospective study that examined the characteristics, electroencephalographic findings, and imaging features of seven patients with LP and intracranial calcifications or epilepsy, four patients had epilepsy, with onset before 10 years of age in three [
         <a href="#rid25">
          25
         </a>
         ]. Focal seizures characterized by a loss of awareness, little motor phenomena, and auras, including déjà vu and rising epigastric sensation, were the most common type of seizures. The majority of these patients had a drug-resistant epilepsy at 10 years of follow-up. (See
         <a class="medical medical_review" href="/z/d/html/2231.html" rel="external">
          "Focal epilepsy: Causes and clinical features"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4004828846">
         <span class="h3">
          Neuroimaging findings
         </span>
         <span class="headingEndMark">
          —
         </span>
         Intracranial horn-shaped mesiotemporal calcifications involving the amygdala, hippocampus, parahippocampal gyrus, and corpus striatum can be detected in patients with LP by computed tomography (CT) scan of the brain [
         <a href="#rid34">
          34
         </a>
         ]. Calcifications of the amygdala are seen in approximately 50 percent of patients with LP and are considered a pathognomonic finding [
         <a href="#rid32">
          32,35
         </a>
         ]. They range from complete (encompassing the basal, basolateral, and basomedial nuclei and the central-medial amygdala) to focal (eg, limited to basolateral nuclei) [
         <a href="#rid26">
          26,27
         </a>
         ].
        </p>
        <p>
         These intracranial calcifications are benign, yet progressive in nature, are more evident in adult patients, and may occur in the absence of neurologic manifestations [
         <a href="#rid25">
          25,35
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3729397719">
         <span class="h2">
          Other extracutaneous manifestations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other extracutaneous manifestations of LP, including ocular, otic, gastrointestinal, urogenital, and endocrine abnormalities, are summarized in the table  (
         <a class="graphic graphic_table graphicRef120746" href="/z/d/graphic/120746.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid36">
          36-38
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2746834173">
         <span class="h1">
          PATHOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Classic histopathologic findings of lesional skin reveal the prominent deposition of an eosinophilic, periodic acid-Schiff (PAS)-positive hyaline material in the papillary dermis as well as around the blood vessels  (
         <a class="graphic graphic_picture graphicRef120747" href="/z/d/graphic/120747.html" rel="external">
          picture 7
         </a>
         ). The overlying epidermis may be acanthotic. A compact papillary dermis and fibrillar deposits in the mid-dermis can be seen on scanning electron microscopy. Transmission electron microscopy shows the deposition of clusters of cord-like, fibrillar material in the dermis between the collagen and the elastic fibers. This fibrillary material can also be seen within the cytoplasm of dermal fibroblasts [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
         A biopsy of the early vesicular lesions that occur in childhood and infancy reveals acantholytic keratinocytes within the epidermis with dilated intercellular spaces between keratinocytes [
         <a href="#rid22">
          22
         </a>
         ]. Electron microscopy examination of these vesicular lesions shows "free-floating" desmosomes within the widened intercellular space and intact hemidesmosomes attached to the basal lamina [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1900629151">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         A diagnosis of lipoid proteinosis (LP) should be suspected in an infant with a weak cry and persistent hoarseness in the first year of life. In older individuals, the diagnosis is suspected based on the presence of some or all of the following findings:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         History of hoarseness and a weak cry since infancy, accompanied by a woody and enlarged tongue with limited protrusion  (
         <a class="graphic graphic_picture graphicRef120701" href="/z/d/graphic/120701.html" rel="external">
          picture 1A
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Typical cutaneous findings of facial acneiform scars  (
         <a class="graphic graphic_picture graphicRef120726" href="/z/d/graphic/120726.html" rel="external">
          picture 3
         </a>
         ), beaded papules on the eyelid margin  (
         <a class="graphic graphic_picture graphicRef120730 graphicRef120728" href="/z/d/graphic/120730.html" rel="external">
          picture 4A-B
         </a>
         ), and verrucous plaques over areas of friction  (
         <a class="graphic graphic_picture graphicRef120733" href="/z/d/graphic/120733.html" rel="external">
          picture 5
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A positive family history of LP and/or a history of parental consanguinity
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Horn-shaped mesiotemporal calcifications on brain imaging (see
         <a class="local">
          'Neuroimaging findings'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A history of seizures
        </p>
        <p>
        </p>
        <p>
         Dermoscopy may be helpful in visualizing subtle, almost nonapparent clinically, beaded papules along the eyelid  (
         <a class="graphic graphic_picture graphicRef130649" href="/z/d/graphic/130649.html" rel="external">
          picture 6
         </a>
         ) [
         <a href="#rid24">
          24,40
         </a>
         ].
        </p>
        <p>
         A lesional skin biopsy showing typical infiltration of the papillary dermis with periodic acid-Schiff (PAS)-positive hyaline material  (
         <a class="graphic graphic_picture graphicRef120747" href="/z/d/graphic/120747.html" rel="external">
          picture 7
         </a>
         ) supports the diagnosis of LP. (See
         <a class="local">
          'Pathology'
         </a>
         above.)
        </p>
        <p>
         The identification of biallelic loss-of-function variants in the extracellular matrix protein
         <em>
          ECM1
         </em>
         gene, located on chromosome 1q21.2, provides the definitive diagnosis of LP [
         <a href="#rid3">
          3,41
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3163414558">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis of lipoid proteinosis (LP) includes:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Other causes of persistent hoarseness in infancy (see
         <a class="medical medical_review" href="/z/d/html/6304.html" rel="external">
          "Hoarseness in children: Evaluation"
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Laryngeal hemangiomas
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Laryngeal cysts
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Vocal cord paralysis
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Vocal cord hypertrophy
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Diseases associated with macroglossia with lateral crenations:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Systemic amyloidosis (see
         <a class="medical medical_review" href="/z/d/html/5589.html" rel="external">
          "Overview of amyloidosis"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Congenital hypothyroidism (see
         <a class="medical medical_review" href="/z/d/html/5836.html" rel="external">
          "Clinical features and detection of congenital hypothyroidism"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Acromegaly (see
         <a class="medical medical_review" href="/z/d/html/6633.html" rel="external">
          "Causes and clinical manifestations of acromegaly"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Myxedema (see
         <a class="medical medical_review" href="/z/d/html/7846.html" rel="external">
          "Clinical manifestations of hypothyroidism"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Infiltrated verrucous plaques over frictional areas includes the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Xanthomas  (
         <a class="graphic graphic_picture graphicRef104992" href="/z/d/graphic/104992.html" rel="external">
          picture 8
         </a>
         ) (see
         <a class="medical medical_review" href="/z/d/html/13786.html" rel="external">
          "Cutaneous xanthomas"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Nodular localized cutaneous amyloidosis  (
         <a class="graphic graphic_picture graphicRef109625" href="/z/d/graphic/109625.html" rel="external">
          picture 9
         </a>
         ) (see
         <a class="medical medical_review" href="/z/d/html/13759.html" rel="external">
          "Cutaneous manifestations of amyloidosis"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Lepromatous leprosy – lepromas and cobblestoning of the oral mucosa (see
         <a class="medical medical_review" href="/z/d/html/5348.html" rel="external">
          "Leprosy: Epidemiology, microbiology, clinical manifestations, and diagnosis"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Papular mucinosis (also known as lichen myxedematosus) (see
         <a class="medical medical_review" href="/z/d/html/110154.html" rel="external">
          "Localized lichen myxedematosus"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Other blistering disease in children that heal with scarring:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Epidermolysis bullosa simplex  (
         <a class="graphic graphic_picture graphicRef86392" href="/z/d/graphic/86392.html" rel="external">
          picture 10
         </a>
         ) (see
         <a class="medical medical_review" href="/z/d/html/15449.html" rel="external">
          "Epidermolysis bullosa: Epidemiology, pathogenesis, classification, and clinical features", section on 'Epidermolysis bullosa simplex'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Erythropoietic protoporphyria  (
         <a class="graphic graphic_picture graphicRef98730" href="/z/d/graphic/98730.html" rel="external">
          picture 11
         </a>
         ) (see
         <a class="medical medical_review" href="/z/d/html/7125.html" rel="external">
          "Erythropoietic protoporphyria and X-linked protoporphyria"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hydroa vacciniforme (see
         <a class="medical medical_review" href="/z/d/html/6622.html" rel="external">
          "Photosensitivity disorders (photodermatoses): Clinical manifestations, diagnosis, and treatment", section on 'Hydroa vacciniforme'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Incontinentia pigmenti  (
         <a class="graphic graphic_picture graphicRef58769" href="/z/d/graphic/58769.html" rel="external">
          picture 12
         </a>
         ) (see
         <a class="medical medical_review" href="/z/d/html/15513.html" rel="external">
          "Incontinentia pigmenti"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Bullous bite reaction (see
         <a class="medical medical_review" href="/z/d/html/4088.html" rel="external">
          "Insect and other arthropod bites"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H370581157">
         <span class="h1">
          MANAGEMENT
         </span>
        </p>
        <p class="headingAnchor" id="H4247594940">
         <span class="h2">
          General approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         The management of patients with lipoid proteinosis (LP) should be individualized based on the characteristics of the individual affected. In most cases, it requires a multidisciplinary approach that may involve a dermatologist; ear, nose, and throat specialist; neurologist; psychiatrist; ophthalmologist; dentist; and geneticist.
        </p>
        <p>
         We will discuss the treatment of cutaneous and mucosal manifestations of LP. The management of neuropsychiatric and other extracutaneous manifestations of LP is beyond the scope of this topic.
        </p>
        <p class="headingAnchor" id="H2599974288">
         <span class="h2">
          Treatment of mucocutaneous manifestations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Medical and surgical treatment of mucosal and cutaneous manifestations of LP is directed at providing symptomatic relief and cosmetic improvement. Because of the rarity of the disease, there are no randomized trials evaluating interventions for LP, and treatment is based on limited evidence from case series and case reports and clinical experience.
        </p>
        <p class="headingAnchor" id="H3042536803">
         <span class="h3">
          Medical therapies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Systemic retinoids, such as
         <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">
          acitretin
         </a>
         0.5 mg/kg per day, are a reasonable first-line treatment for the cutaneous and laryngeal manifestations of LP in patients in whom systemic retinoids are not contraindicated. Long-term treatment may be required. However, the optimal duration of treatment has not been determined, and data on the recurrence of symptoms after discontinuation of treatment as well as long-term follow-up data are lacking.
        </p>
        <p>
         The use of
         <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">
          acitretin
         </a>
         for LP has been described in many case reports with variable response [
         <a href="#rid42">
          42-48
         </a>
         ]. In the largest series including 10 patients treated with acitretin 0.5 mg/kg per day for six months, seven patients reported a softening of their infiltrated cutaneous papulonodules, seven had an improvement of their voice quality, three had a decrease in oral ulcerations, and three reported an improvement in cutaneous scarring [
         <a href="#rid46">
          46
         </a>
         ]. In other reports, acitretin improved hoarseness but had no effect on cutaneous findings [
         <a href="#rid42">
          42,44
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">
          Acitretin
         </a>
         is a known teratogen and should be avoided in pregnant women and women of childbearing potential who intend to become pregnant within three years after discontinuation of treatment. For additional information on side effects and monitoring, refer to the Lexicomp drug information monograph included within UpToDate.
        </p>
        <p>
         Other symptomatic treatments that have been reported for LP include intralesional and topical corticosteroids [
         <a href="#rid49">
          49
         </a>
         ], oral
         <a class="drug drug_general" data-topicid="8898" href="/z/d/drug information/8898.html" rel="external">
          dimethyl sulfoxide
         </a>
         [
         <a href="#rid50">
          50
         </a>
         ], etretinate [
         <a href="#rid51">
          51
         </a>
         ], and
         <a class="drug drug_general" data-topicid="9747" href="/z/d/drug information/9747.html" rel="external">
          D-penicillamine
         </a>
         [
         <a href="#rid52">
          52
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2648696211">
         <span class="h3">
          Surgical therapies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Surgical approaches using either carbon dioxide (CO
         <sub>
          2
         </sub>
         ) laser or cryotherapy are an option for the treatment of laryngeal hyaline deposits [
         <a href="#rid53">
          53,54
         </a>
         ]. In a review of 20 published cases, approximately 70 percent experienced improvement of hoarseness [
         <a href="#rid53">
          53
         </a>
         ]. However, the time to relapse after treatment is unknown, and long-term follow-up data are lacking. One report highlighted the importance of combining surgical interventions with voice therapy for an optimal result [
         <a href="#rid54">
          54
         </a>
         ]. Tracheostomy has been used to manage airway compromise [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p>
         CO
         <sub>
          2
         </sub>
         laser, erbium-doped yttrium aluminum garnet (Er:YAG) ablative laser, and dermabrasion have been used in a few patients for the treatment of the cosmetically disfiguring facial scarring and moniliform blepharosis [
         <a href="#rid55">
          55-57
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H373811821">
         <span class="h2">
          Genetic counseling
         </span>
         <span class="headingEndMark">
          —
         </span>
         Consultation with a clinical geneticist is key for accurate diagnosis and reproductive counseling. After a diagnostic visit, an updated genetic consultation is recommended prior to childbearing years, so that the affected individual can better understand their own reproductive risk and options [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H196585384">
         <span class="h1">
          PROGNOSIS AND FOLLOW-UP
         </span>
         <span class="headingEndMark">
          —
         </span>
         Lipoid proteinosis (LP) is not associated with increased risk of malignancy, and the life expectancy of affected individuals is normal, except in the rare occurrence of airway compromise [
         <a href="#rid7">
          7,21
         </a>
         ]. However, the neurologic and psychiatric manifestations of the disease may result in psychosocial dysfunction and diminished quality of life for these patients [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p>
         Individuals with LP should be followed by an otolaryngologist for periodic assessment of the vocal cords and upper airways. Children with LP should be followed up routinely, with a special focus on their developmental milestones and psychomotor development. Brain imaging may be warranted if the patient is symptomatic, keeping in mind that mesiotemporal calcifications are more common in patients older than 10 years [
         <a href="#rid35">
          35
         </a>
         ]. (See
         <a class="local">
          'Neuroimaging findings'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H996613820">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition and pathogenesis
         </strong>
         – Lipoid proteinosis (LP) is a rare autosomal recessive genodermatosis caused by variants in the extracellular matrix protein gene (
         <em>
          ECM1
         </em>
         ). (See
         <a class="local">
          'Introduction'
         </a>
         above and
         <a class="local">
          'Genetics and pathogenesis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical presentation
         </strong>
         – The hallmark clinical manifestations of LP include hoarseness and a weak cry since infancy, the development of a woody and enlarged, crenated tongue with limited protrusion  (
         <a class="graphic graphic_picture graphicRef120701 graphicRef120731" href="/z/d/graphic/120701.html" rel="external">
          picture 1A-B
         </a>
         ), acne-like facial scarring  (
         <a class="graphic graphic_picture graphicRef120726" href="/z/d/graphic/120726.html" rel="external">
          picture 3
         </a>
         ), pearly papules over the eyelid border (moniliform blepharosis)  (
         <a class="graphic graphic_picture graphicRef120730" href="/z/d/graphic/120730.html" rel="external">
          picture 4A
         </a>
         ), and infiltrated papulonodules over the skin. (See
         <a class="local">
          'Mucocutaneous manifestations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Neurologic manifestations of LP include seizures, migraine, schizophrenia, anxiety, panic attacks, impaired memory, and abnormal emotional responses to perceived danger and fear. (See
         <a class="local">
          'Neurologic manifestations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – The diagnosis of LP is based on typical clinical manifestations as well as histopathologic findings of periodic acid-Schiff (PAS)-positive hyaline material within lesional skin and mucosae. The finding of horn-shaped calcifications in the mesiotemporal area on brain imaging is considered pathognomonic of LP. The identification of biallelic loss-of-function variants in the
         <em>
          ECM1
         </em>
         gene by genetic testing provides the definitive diagnosis. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management
         </strong>
         – The management of patients with LP requires a multidisciplinary approach that may involve a dermatologist, otolaryngologist, neurologist, psychiatrist, ophthalmologist, and dentist. Systemic retinoids, such as
         <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">
          acitretin
         </a>
         at the dose of 0.5 mg/kg per day, may be beneficial for improvement of hoarseness, cutaneous infiltrated lesions, and acne-like scarring. Surgical modalities, including laser therapy and cryosurgery, have also been used for the management of laryngeal hyaline deposits and hoarseness. (See
         <a class="local">
          'Management'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prognosis
         </strong>
         – Patients with LP generally have a normal life expectancy. However, the neurologic and psychiatric manifestations of the disease may result in psychosocial dysfunction and diminished quality of life for these patients. (See
         <a class="local">
          'Prognosis and follow-up'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Urbach E, Wiethe C. Lipoidosis cutis et mucosae. Virchows Arch A Pathol Pathol Anat 1929; 273:285.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mcgrath JA. Lipoid proteinosis. Handb Clin Neurol 2015; 132:317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hamada T, McLean WH, Ramsay M, et al. Lipoid proteinosis maps to 1q21 and is caused by mutations in the extracellular matrix protein 1 gene (ECM1). Hum Mol Genet 2002; 11:833.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Hougenhouck-Tulleken W, Chan I, Hamada T, et al. Clinical and molecular characterization of lipoid proteinosis in Namaqualand, South Africa. Br J Dermatol 2004; 151:413.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shah JS, Shah HA. Lipoid proteinosis: Review of Indian cases. J Oral Maxillofac Pathol 2022; 26:236.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Youssefian L, Vahidnezhad H, Daneshpazhooh M, et al. Lipoid proteinosis: phenotypic heterogeneity in Iranian families with c.507delT mutation in ECM1. Exp Dermatol 2015; 24:220.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chan I, Liu L, Hamada T, et al. The molecular basis of lipoid proteinosis: mutations in extracellular matrix protein 1. Exp Dermatol 2007; 16:881.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hamada T, Wessagowit V, South AP, et al. Extracellular matrix protein 1 gene (ECM1) mutations in lipoid proteinosis and genotype-phenotype correlation. J Invest Dermatol 2003; 120:345.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rey LK, Kohlhase J, Möllenhoff K, et al. A Novel ECM1 Splice Site Mutation in Lipoid Proteinosis: Case Report plus Review of the Literature. Mol Syndromol 2016; 7:26.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smits P, Ni J, Feng P, et al. The human extracellular matrix gene 1 (ECM1): genomic structure, cDNA cloning, expression pattern, and chromosomal localization. Genomics 1997; 45:487.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horev L, Potikha T, Ayalon S, et al. A novel splice-site mutation in ECM-1 gene in a consanguineous family with lipoid proteinosis. Exp Dermatol 2005; 14:891.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sercu S, Lambeir AM, Steenackers E, et al. ECM1 interacts with fibulin-3 and the beta 3 chain of laminin 332 through its serum albumin subdomain-like 2 domain. Matrix Biol 2009; 28:160.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fujimoto N, Terlizzi J, Aho S, et al. Extracellular matrix protein 1 inhibits the activity of matrix metalloproteinase 9 through high-affinity protein/protein interactions. Exp Dermatol 2006; 15:300.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kowalewski C, Kozłowska A, Chan I, et al. Three-dimensional imaging reveals major changes in skin microvasculature in lipoid proteinosis and lichen sclerosus. J Dermatol Sci 2005; 38:215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uchida T, Hayashi H, Inaoki M, et al. A failure of mucocutaneous lymphangiogenesis may underlie the clinical features of lipoid proteinosis. Br J Dermatol 2007; 156:152.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taskin S, Celik H, Taskin A, et al. Assessment of dynamic thiol-disulfide homeostasis in patients with lipoid proteinosis (Urbach-Wiethe syndrome). Rev Assoc Med Bras (1992) 2022; 68:1259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee KC, Peters SM, Ko YCK, et al. Oral manifestations of lipoid proteinosis in a 10-year-old female: A case report and literature update. Oral Surg Oral Med Oral Pathol Oral Radiol 2018; 126:e228.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deshpande P, Guledgud MV, Patil K, et al. Lipoid proteinosis: a rare encounter in dental office. Case Rep Dent 2015; 2015:670369.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frenkel B, Vered M, Taicher S, Yarom N. Lipoid proteinosis unveiled by oral mucosal lesions: a comprehensive analysis of 137 cases. Clin Oral Investig 2017; 21:2245.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xu XT, Chen Q, Siong-See Lee J. Lipoid proteinosis in a Chinese patient. Am J Dermatopathol 2014; 36:e108.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cote DN. Head and neck manifestations of lipoid proteinosis. Otolaryngol Head Neck Surg 1998; 119:144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dyer JA, Yu QC, Paller AS. "Free-floating" desmosomes in lipoid proteinosis: an inherent defect in keratinocyte adhesion? Pediatr Dermatol 2006; 23:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hamie L, Knio Z, Abbas O, et al. Clinical clues early in the lives of individuals with lipoid proteinosis can determine the course of the disease. Clin Exp Dermatol 2017; 42:428.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tabassum H, Mushtaq S, Amin SS, et al. Lipoid Proteinosis with Esotropia: Report of a Rare Case and Dermoscopic Findings. Indian J Dermatol 2020; 65:53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oguz Akarsu E, Dinçsoy Bir F, Baykal C, et al. The Characteristics and Long-Term Course of Epilepsy in Lipoid Proteinosis: A Spectrum From Mild to Severe Seizures in Relation to ECM1 Mutations. Clin EEG Neurosci 2018; 49:192.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koen N, Fourie J, Terburg D, et al. Translational neuroscience of basolateral amygdala lesions: Studies of Urbach-Wiethe disease. J Neurosci Res 2016; 94:504.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feinstein JS, Adolphs R, Damasio A, Tranel D. The human amygdala and the induction and experience of fear. Curr Biol 2011; 21:34.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Terburg D, Morgan BE, Montoya ER, et al. Hypervigilance for fear after basolateral amygdala damage in humans. Transl Psychiatry 2012; 2:e115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adolphs R, Tranel D. Amygdala damage impairs emotion recognition from scenes only when they contain facial expressions. Neuropsychologia 2003; 41:1281.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Macedo CE, Cuadra G, Molina V, Brandão ML. Aversive stimulation of the inferior colliculus changes dopamine and serotonin extracellular levels in the frontal cortex: modulation by the basolateral nucleus of amygdala. Synapse 2005; 55:58.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tye KM, Prakash R, Kim SY, et al. Amygdala circuitry mediating reversible and bidirectional control of anxiety. Nature 2011; 471:358.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meletti S, Cantalupo G, Santoro F, et al. Temporal lobe epilepsy and emotion recognition without amygdala: a case study of Urbach-Wiethe disease and review of the literature. Epileptic Disord 2014; 16:518.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thornton HB, Nel D, Thornton D, et al. The neuropsychiatry and neuropsychology of lipoid proteinosis. J Neuropsychiatry Clin Neurosci 2008; 20:86.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gonçalves FG, de Melo MB, de L Matos V, et al. Amygdalae and striatum calcification in lipoid proteinosis. AJNR Am J Neuroradiol 2010; 31:88.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Appenzeller S, Chaloult E, Velho P, et al. Amygdalae calcifications associated with disease duration in lipoid proteinosis. J Neuroimaging 2006; 16:154.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yukkaldıran A, An İ, Erdoğan O. Evaluation of cochlear involvement and hearing function in lipoid proteinosis patients. J Cosmet Dermatol 2021; 20:2259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Özgür A, An İ. Evaluation of choroidal thickness and ocular manifestations in lipoid proteinosis. Int Ophthalmol 2023; 43:239.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Custódio Lima J, Nagasako CK, Montes CG, et al. Gastrointestinal involvement in lipoid proteinosis: a ten-year follow-up of a brazilian female patient. Case Rep Med 2014; 2014:952038.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Almeida HL Jr, Rodeghiero RG, Suzuki PNA, Ogawa MM. Ultrastructural aspects of the skin in lipoid proteinosis (Urbach-Wiethe disease). An Bras Dermatol 2021; 96:730.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ray A, Agrawal I, Singh BS, Kar BR. Novel features in dermoscopy of lipoid proteinosis. Indian J Dermatol Venereol Leprol 2023; 89:116.
          </a>
         </li>
         <li class="breakAll">
          Vahidnezhad H, Youssefian L, Uitto J. Lipoid proteinosis. In: GeneReviews, Adam MP, Ardinger HH, Pagon RA, et al (Eds), University of Washington, Seattle, Seattle (WA) 1993.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Toosi S, Ehsani AH. Treatment of lipoid proteinosis  with acitretin: a case report. J Eur Acad Dermatol Venereol 2009; 23:482.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Larkin S, Blixt EK, Kumar N, et al. Lipoid proteinosis: Unfamiliar skin findings delay diagnosis. JAAD Case Rep 2018; 4:609.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gündüz O, Sahiner N, Atasoy P, Senyücel C. Acitretin treatment for lipoid proteinosis. Case Rep Dermatol Med 2012; 2012:324506.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Akoglu G, Karaduman A, Ergin S, et al. Clinical and histopathological response to acitretin therapy in lipoid proteinosis. J Dermatolog Treat 2011; 22:178.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dertlioğlu SB, Çalık M, Çiçek D. Demographic, clinical, and radiologic signs and treatment responses of lipoid proteinosis patients: a 10-case series from Şanlıurfa. Int J Dermatol 2014; 53:516.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bakry OA, Samaka RM, Houla NS, Basha MA. Two Egyptian cases of lipoid proteinosis successfully treated with acitretin. J Dermatol Case Rep 2014; 8:29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carnevale C, Castiglia D, Diociaiuti A, et al. Lipoid Proteinosis: A Previously Unrecognized Mutation and Therapeutic Response to Acitretin. Acta Derm Venereol 2017; 97:1249.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang R, Liu Y, Xue Y, et al. Treatment of lipoid proteinosis due to the p.C220G mutation in ECM1, a major allele in Chinese patients. J Transl Med 2014; 12:85.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang XP, Huo J, Liu Y, et al. A Chinese family with lipoid proteinosis resulting from a homozygous missense mutation in the extracellular matrix protein 1 gene. J Eur Acad Dermatol Venereol 2009; 23:1336.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gruber F, Manestar D, Stasic A, Grgurevic Z. Treatment of lipoid proteinosis with etretinate. Acta Derm Venereol 1996; 76:154.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaya TI, Kokturk A, Tursen U, et al. D-penicillamine treatment for lipoid proteinosis. Pediatr Dermatol 2002; 19:359.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loos E, Kerkhofs L, Laureyns G. Lipoid Proteinosis: A Rare Cause of Hoarseness. J Voice 2019; 33:155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen Z, Calawerts W, Zhang Y, et al. A Case Report: Hybrid Treatment Approach to Lipoid Proteinosis of the Larynx. J Voice 2017; 31:128.e15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosenthal G, Lifshitz T, Monos T, et al. Carbon dioxide laser treatment for lipoid proteinosis (Urbach-Wiethe syndrome) involving the eyelids. Br J Ophthalmol 1997; 81:253.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Çalıskan E, Açıkgöz G, Tunca M, et al. Treatment of lipoid proteinosis with ablative Er:YAG laser resurfacing. Dermatol Ther 2015; 28:291.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buchan NG, Kemble JV. Successful surgical treatment of lipoid proteinosis. Br J Dermatol 1974; 90:561.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 15517 Version 3.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Lipoidosis cutis et mucosae
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26564090" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Lipoid proteinosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11929856" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Lipoid proteinosis maps to 1q21 and is caused by mutations in the extracellular matrix protein 1 gene (ECM1).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15327549" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Clinical and molecular characterization of lipoid proteinosis in Namaqualand, South Africa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35968171" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Lipoid proteinosis: Review of Indian cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25529926" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Lipoid proteinosis: phenotypic heterogeneity in Iranian families with c.507delT mutation in ECM1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17927570" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : The molecular basis of lipoid proteinosis: mutations in extracellular matrix protein 1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12603844" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Extracellular matrix protein 1 gene (ECM1) mutations in lipoid proteinosis and genotype-phenotype correlation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27194970" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : A Novel ECM1 Splice Site Mutation in Lipoid Proteinosis: Case Report plus Review of the Literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9367673" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : The human extracellular matrix gene 1 (ECM1): genomic structure, cDNA cloning, expression pattern, and chromosomal localization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16274456" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : A novel splice-site mutation in ECM-1 gene in a consanguineous family with lipoid proteinosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19275936" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : ECM1 interacts with fibulin-3 and the beta 3 chain of laminin 332 through its serum albumin subdomain-like 2 domain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16512877" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Extracellular matrix protein 1 inhibits the activity of matrix metalloproteinase 9 through high-affinity protein/protein interactions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15927815" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Three-dimensional imaging reveals major changes in skin microvasculature in lipoid proteinosis and lichen sclerosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17199583" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : A failure of mucocutaneous lymphangiogenesis may underlie the clinical features of lipoid proteinosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36134773" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Assessment of dynamic thiol-disulfide homeostasis in patients with lipoid proteinosis (Urbach-Wiethe syndrome).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29548668" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Oral manifestations of lipoid proteinosis in a 10-year-old female: A case report and literature update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25874136" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Lipoid proteinosis: a rare encounter in dental office.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27900487" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Lipoid proteinosis unveiled by oral mucosal lesions: a comprehensive analysis of 137 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24521736" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Lipoid proteinosis in a Chinese patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9674530" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Head and neck manifestations of lipoid proteinosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16445401" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : "Free-floating" desmosomes in lipoid proteinosis: an inherent defect in keratinocyte adhesion?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28244239" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Clinical clues early in the lives of individuals with lipoid proteinosis can determine the course of the disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32029942" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Lipoid Proteinosis with Esotropia: Report of a Rare Case and Dermoscopic Findings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28434238" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : The Characteristics and Long-Term Course of Epilepsy in Lipoid Proteinosis: A Spectrum From Mild to Severe Seizures in Relation to ECM1 Mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27091312" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Translational neuroscience of basolateral amygdala lesions: Studies of Urbach-Wiethe disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21167712" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : The human amygdala and the induction and experience of fear.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22832959" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Hypervigilance for fear after basolateral amygdala damage in humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12757901" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Amygdala damage impairs emotion recognition from scenes only when they contain facial expressions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15515004" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Aversive stimulation of the inferior colliculus changes dopamine and serotonin extracellular levels in the frontal cortex: modulation by the basolateral nucleus of amygdala.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21389985" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Amygdala circuitry mediating reversible and bidirectional control of anxiety.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25465029" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Temporal lobe epilepsy and emotion recognition without amygdala: a case study of Urbach-Wiethe disease and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18305289" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : The neuropsychiatry and neuropsychology of lipoid proteinosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19696137" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Amygdalae and striatum calcification in lipoid proteinosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16629738" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Amygdalae calcifications associated with disease duration in lipoid proteinosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33174327" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Evaluation of cochlear involvement and hearing function in lipoid proteinosis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35842887" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Evaluation of choroidal thickness and ocular manifestations in lipoid proteinosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25045357" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Gastrointestinal involvement in lipoid proteinosis: a ten-year follow-up of a brazilian female patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34544637" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Ultrastructural aspects of the skin in lipoid proteinosis (Urbach-Wiethe disease).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36331838" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Novel features in dermoscopy of lipoid proteinosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36331838" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Novel features in dermoscopy of lipoid proteinosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18808438" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Treatment of lipoid proteinosis  with acitretin: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30003130" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Lipoid proteinosis: Unfamiliar skin findings delay diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23259080" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Acitretin treatment for lipoid proteinosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20666665" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Clinical and histopathological response to acitretin therapy in lipoid proteinosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24320796" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Demographic, clinical, and radiologic signs and treatment responses of lipoid proteinosis patients: a 10-case series fromŞanlıurfa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24748909" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Two Egyptian cases of lipoid proteinosis successfully treated with acitretin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28681064" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Lipoid Proteinosis: A Previously Unrecognized Mutation and Therapeutic Response to Acitretin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24708644" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Treatment of lipoid proteinosis due to the p.C220G mutation in ECM1, a major allele in Chinese patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19368610" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : A Chinese family with lipoid proteinosis resulting from a homozygous missense mutation in the extracellular matrix protein 1 gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8740275" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Treatment of lipoid proteinosis with etretinate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12220287" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : D-penicillamine treatment for lipoid proteinosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30385011" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Lipoid Proteinosis: A Rare Cause of Hoarseness.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27049452" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : A Case Report: Hybrid Treatment Approach to Lipoid Proteinosis of the Larynx.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9135394" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Carbon dioxide laser treatment for lipoid proteinosis (Urbach-Wiethe syndrome) involving the eyelids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26031844" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Treatment of lipoid proteinosis with ablative Er:YAG laser resurfacing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4833793" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Successful surgical treatment of lipoid proteinosis.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
